Zerrin Canturk

Dr. Zerrin Canturk

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 August 2014 in Cytotechnology
Verified
Journal Article
Closed access
PDF file
ZCZerrin Canturk
Zerrin Canturk
YTYağmur Tunali
Yağmur Tunali
SKSeval Korkmaz
Seval Korkmaz
ZGZafer Gulbaş
Zafer Gulbaş

1 January 2018 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
BÇBetül Kaya Çavuşoğlu
Betül Kaya Çavuşoğlu
Leyla YurttasLeyla Yurttas
Leyla Yurttas
ZCZerrin Canturk
Zerrin Canturk

1 January 2018 in Journal of Food and Drug Analysis
Verified
Journal Article
Open access
ZCZerrin Canturk
Zerrin Canturk
This study aimed to investigate the synergy between anticandidal and apoptotic effects of ferulic acid and caspofungin against Candida albicans and Candida glabrata, with the help of a quantitative checkerboard microdilution assay using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) as a viability dye. Apoptotic effects of caspofungin and ferulic acid concentrations (alone and combined) were analyzed for C. albicans and C. glabrata based on annexin V-propidium iodide binding capacities using flow cytometric analysis. C. albicans showed a synergistic effect, represented by a fractional inhibitory concentration index of < 0.5, but C. glabrata showed no synergistic effect (fractional inhibitory concentration index > 0.5). Early and late apoptotic effects of caspofungin and ferulic acid concentrations (1 μg/mL and 1000 μg/mL) were calculated as 55.7% and 18.3%, respectively, while their necrotic effects were determined as 5.8% and 51.6%, respectively, using flow cytometric analyses. The apoptotic effects of the combination of caspofungin and ferulic acid at concentrations of 1 μg/mL and 1000 μg/mL on C. albicans and C. glabrata were 73.0% and 48.7%, respectively. Ferulic acid also demonstrated a synergistic effect in combination with caspofungin against C. albicans. Another possibility is to combine the existing anticandidal drug with phytochemicals to enhance the efficacy of anticandidal drug.

28 October 2020 in Molecules
Verified
Journal Article
Open access
PDF file
Belgin SeverBelgin Sever
Belgin Sever
HSHasan Soybir
Hasan Soybir
ŞGŞENNUR GÖRGÜLÜ
ŞENNUR GÖRGÜLÜ
ZCZerrin Canturk
Zerrin Canturk
Mehlika Dilek AltıntopMehlika Dilek Altıntop
Mehlika Dilek Altıntop
Dipeptidyl peptidase-4 (DPP-4) inhibition has been recognized as a promising approach to develop safe and potent antidiabetic agents for the management of type 2 diabetes. In this context, new thiosemicarbazones (2a–o) were prepared efficiently by the reaction of aromatic aldehydes with 4-[4-(1H-pyrazol-1-yl)phenyl]thiosemicarbazide (1), which was obtained via the reaction of 4-(1H-pyrazol-1-yl)phenyl isothiocyanate with hydrazine hydrate. Compounds 2a–o were evaluated for their DPP-4 inhibitory effects based on a convenient fluorescence-based assay. 4-[4-(1H-pyrazol-1-yl)phenyl]-1-(4-bromobenzylidene)thiosemicarbazide (2f) was identified as the most effective DPP-4 inhibitor in this series with an IC50 value of 1.266 ± 0.264 nM when compared with sitagliptin (IC50 = 4.380 ± 0.319 nM). MTT test was carried out to assess the cytotoxic effects of compounds 2a–o on NIH/3T3 mouse embryonic fibroblast (normal) cell line. According to cytotoxicity assay, compound 2f showed cytotoxicity towards NIH/3T3 cell line with an IC50 value higher than 500 µM pointing out its favourable safety profile. Molecular docking studies indicated that compound 2f presented π-π interactions with Arg358 and Tyr666 via pyrazole scaffold and 4-bromophenyl substituent, respectively. Overall, in vitro and in silico studies put emphasis on that compound 2f attracts a great notice as a drug-like DPP-4 inhibitor for further antidiabetic research.

5 January 2023 in Archiv der Pharmazie
Verified
Journal Article
Closed access
Mehlika Dilek AltıntopMehlika Dilek Altıntop
Mehlika Dilek Altıntop
YDYeliz DEMİR
Yeliz DEMİR
CTCüneyt Türkeş
Cüneyt Türkeş
RÖRemzi B. Öztürk
Remzi B. Öztürk
ZCZerrin Canturk
Zerrin Canturk
Ahmet ÖzdemirAhmet Özdemir
Ahmet Özdemir

30 October 2023 in ACS Omega
Verified
Journal Article
Open access
Mehlika Dilek AltıntopMehlika Dilek Altıntop
Mehlika Dilek Altıntop
ZCZerrin Canturk
Zerrin Canturk
Ahmet ÖzdemirAhmet Özdemir
Ahmet Özdemir
In an attempt to identify small molecules for the treatment of leukemia, 12 new pyrazolines (2a-l) were synthesized efficiently. WST-1 assay was performed to examine their cytotoxic features on HL-60 human acute promyelocytic leukemia (APL), K562 human chronic myeloid leukemia (CML), and THP-1 human acute monocytic leukemia cells. Four compounds (2e, 2f, 2g, and 2h) were determined as promising antileukemic agents on HL-60 and K562 cells. IC50 values of compounds 2f, 2h, 2e, 2g, and bortezomib for the HL-60 cell line were found as 33.52, 42.89, 48.02, 62.34, and 31.75 μM, while IC50 values of compounds 2h, 2g, 2f, 2e, and bortezomib for K562 cells were determined as 33.61, 50.23, 57.28, 76.90, and 42.69 μM, respectively. Further studies were carried out to shed light on the mechanism of antileukemic action. According to the data obtained by in vitro experiments, 1-(4-fluorophenyl)-3-(thiophen-3-yl)-5-(4-(4-methylpiperazin-1-yl)phenyl)-2-pyrazoline (2f) and 1-(3-bromophenyl)-3-(thiophen-3-yl)-5-(4-(4-methylpiperazin-1-yl)phenyl)-2-pyrazoline (2h) have proved to be potential antileukemic agents with remarkable cytotoxicity against HL-60 and K562 cells by activation of caspase 3, thereby inducing apoptosis.